Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 2
2004 2
2005 9
2006 8
2007 12
2008 19
2009 23
2010 34
2011 29
2012 43
2013 61
2014 69
2015 78
2016 98
2017 125
2018 146
2019 184
2020 225
2021 262
2022 289
2023 293
2024 390
2025 476
2026 310

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,851 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial.
Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Arunachalam A, Keller SM, Samkari A, Gao S; KEYNOTE-671 Investigators. Spicer JD, et al. Lancet. 2024 Sep 28;404(10459):1240-1252. doi: 10.1016/S0140-6736(24)01756-2. Epub 2024 Sep 14. Lancet. 2024. PMID: 39288781 Free PMC article. Clinical Trial.
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial.
Yue D, Wang W, Liu H, Chen Q, Chen C, Liu L, Zhang P, Zhao G, Yang F, Han G, Cheng Y, Yu B, Yang Y, Chen H, Jiang J, Tan L, Xu S, Mao N, Hu J, Zhang L, Yao B, Wang S, Wang RH, Zheng W, Wang C; RATIONALE-315 investigators. Yue D, et al. Among authors: yang y. Lancet Respir Med. 2025 Feb;13(2):119-129. doi: 10.1016/S2213-2600(24)00269-8. Epub 2024 Nov 21. Lancet Respir Med. 2025. PMID: 39581197 Clinical Trial.
Acute pancreatitis: mechanisms and therapeutic approaches.
Hu Q, Hu Y, Tan C, Yang Y, Su H, Huang Z, Tang W, Wang R, Liu J, Wan M. Hu Q, et al. Among authors: yang y. Signal Transduct Target Ther. 2026 Jan 14;11(1):15. doi: 10.1038/s41392-025-02394-6. Signal Transduct Target Ther. 2026. PMID: 41530118 Free PMC article. Review.
BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction.
Simanshu DK, Xu R, Stice JP, Czyzyk DJ, Feng S, Denson JP, Riegler E, Yang Y, Zhang C, Donovan S, Smith BP, Abreu-Blanco M, Chen M, Feng C, Fu L, Rabara D, Young LC, Dyba M, Yan W, Lin K, Ghorbanpoorvalukolaie S, Larsen EK, Malik W, Champagne A, Parker K, Ju JH, Jeknic S, Esposito D, Turner DM, Lightstone FC, Wang B, Wehn PM, Wang K, Stephen AG, Maciag AE, Hata AN, Sinkevicius KW, Nissley DV, Wallace EM, McCormick F, Beltran PJ. Simanshu DK, et al. Among authors: yang y. Science. 2025 Jul 24;389(6758):409-415. doi: 10.1126/science.adq2004. Epub 2025 Jun 12. Science. 2025. PMID: 40504949
Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer.
Wu YL, Hochmair M, Yang Y, Yang XN, Tsuboi M, Paz-Ares L, Yang JC, Wu L, Kim HR, Rieke DT, Johnson M, Besse B, Sharma N, Maeda P, Peterson P, Lin BK, Frimodt-Moller B, Goldman J, Drilon A; LIBRETTO-432 Trial Investigators. Wu YL, et al. N Engl J Med. 2026 Aug 13;395(7):660-670. doi: 10.1056/NEJMoa2602628. Epub 2026 May 31. N Engl J Med. 2026. PMID: 42223087 Clinical Trial.
Cold-Adapted Nanozymes.
Zhang T, Lu M, Yang Y, Ji X, Gu H, Sun Y, Chen C, Sun T. Zhang T, et al. Among authors: yang y. Adv Healthc Mater. 2025 Sep;14(25):e2501211. doi: 10.1002/adhm.202501211. Epub 2025 Jul 7. Adv Healthc Mater. 2025. PMID: 40624894 Review.
Anthocyanins Prevent Mastitis Exacerbation by Inhibiting PANoptosis Activation.
Feng R, Guo L, Wang F, Zhang Q, Wang G, Huang H, Du W, An H, Yang Y, Miao H, Zheng P, Chu T, Zhang D, Yan X, Mi X, Ma Q, Gao W, Li Y, Li S, Zhang Y, Zhu Z, Wang Y, Liu J, Liu X. Feng R, et al. Among authors: yang y. Adv Sci (Weinh). 2025 Sep;12(33):e07172. doi: 10.1002/advs.202507172. Epub 2025 Jun 24. Adv Sci (Weinh). 2025. PMID: 40552401 Free PMC article.
2,851 results